treatment advances in achieving remission in mild to moderate ulcerative colitis

Treatment Advances in Achieving Remission in Mild to

Moderate Ulcerative Colitis

Goals of Therapy for Patients With UC

Sequential Therapies for UC

Oral 5-ASA Formulations: Sites of Delivery

Conventional Corticosteroids in UC

Corticosteroids: Dependency—Short- and Long-term Efficacy

CORE I and II: Budesonide MMX Primary End Point: Combined Clinical and Endoscopic

Remission

Azathioprine vs 5-ASA for Corticosteroid-Dependent, Active

UC

Anti-TNF Therapies for Moderate to Severe Disease

Treatment Algorithm to Maximize Remission and Minimize

Corticosteroid Dependence in UC

Patient Case

Mesalamine Safety

Patient Case (cont)

Pooled Safety Data: Adverse Effects of Budesonide MMX in Patients With Active UC

Anti-TNF Agents: Adverse Events

Minimizing Toxicity for Anti-TNF Therapy

Summary: Safety

Effect on Bone Density

Monitoring the Patient Receiving Budesonide MMX

Summary: Safety of Agents Used to Induce Remission in Mild to

Moderate UC

Abbreviations

References

References (cont)

References (cont)